Palbociclibe Now Available via SUS for Advanced Breast Cancer in Ceará
A significant step forward in cancer care in Brazil has been achieved with the availability of Palbociclibe, a targeted therapy, through the CRIO – Centro Regional Integrado de Oncologia in Ceará. This marks the first time the medication has been offered publicly within the state, expanding access to a novel treatment option for advanced or metastatic breast cancer within the public healthcare system.
The implementation of Palbociclibe access follows its inclusion in the Sistema Único de Saúde (SUS), Brazil’s unified health system, in 2021. However, the practical availability has been contingent on the establishment of a financial and administrative framework. Recently, the creation of the APAC (Autorização de Procedimentos de Alta Complexidade) – a mechanism for authorizing and funding high-cost treatments – has enabled hospitals like CRIO to acquire and distribute the medication.
According to a statement from the institution, “No CRIO, essa conquista se traduz em ação: nossas pacientes já estão recebendo o Palbociclibe pelo SUS.” This translates to: “At CRIO, this achievement translates into action: our patients are already receiving Palbociclibe through SUS.” This demonstrates a direct and immediate impact on patient care.
Palbociclibe is categorized as a next-generation targeted therapy, specifically indicated for patients diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer. This subtype represents a predominant profile among advanced cases of the disease. The medication functions by blocking proteins responsible for the proliferation of tumor cells, aiming to slow disease progression and extend the period of tumor control, ultimately improving a patient’s quality of life.
The drug, Palbociclibe (marketed as Ibrance), is registered with Brazil’s regulatory agency, ANVISA, and is typically used in combination with endocrine therapy. As noted in available resources, it can also be prescribed “off label” – meaning for conditions beyond those specifically listed in the official product information – if supported by scientific evidence.
The cost of Palbociclibe can be substantial, ranging from approximately R$8,000 to R$23,000 (as of October 2023), making it inaccessible to many patients without public funding. The availability through SUS is therefore a critical development for equitable access to this treatment.
CRIO has emphasized its commitment to providing cutting-edge oncology care, stating, “Seguimos comprometidos em buscar, incorporar e oferecer sempre o que há de melhor na oncologia, unindo ciência, inovação e cuidado humano para quem confia sua vida a nós.” This translates to: “We remain committed to seeking, incorporating, and offering the best in oncology, uniting science, innovation, and human care for those who entrust their lives to us.” This highlights the institution’s dedication to integrating advanced medical technology with compassionate patient care.
The broader context of breast cancer treatment disparities in Brazil is also coming into focus. Recent research, published in Curr Oncol in August 2025, highlights challenges in access to care, including variations in drug availability through SUS. This underscores the importance of initiatives like the one at CRIO in addressing these inequalities.
While Palbociclibe represents a significant advancement, it’s important to remember that treatment decisions are highly individualized. The suitability of this medication, or any cancer therapy, depends on a variety of factors, including the specific characteristics of the cancer, the patient’s overall health, and prior treatments received. Patients should discuss all treatment options and potential benefits and risks with their healthcare team.
The increased availability of Palbociclibe through SUS at CRIO represents a positive step towards improving outcomes for patients with advanced breast cancer in Brazil, offering a new avenue for treatment and hope for extended disease control and improved quality of life.